Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Valproic Acid: second generation.

Meir Bialer1, Boris Yagen

  • 1Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel. bialer@md.huji.ac.il

Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|January 3, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of CYP2C9 activity between Ethiopian and non-Ethiopian Jews: an interethnic study of (<i>S</i>)-warfarin pharmacokinetic and pharmacodynamic.

Frontiers in pharmacology·2026
Same author

Antiseizure Medications that Did Not Reach the Epilepsy Market: An Assessment of Factors Contributing to Their Failed Clinical Development Over the Last Three Decades.

Drugs·2026
Same author

Utilization of Apixaban Pharmacokinetics for Dose Optimization in High-Risk Elderly Patients.

Clinical pharmacokinetics·2026
Same author

Enantioselective comparative analysis of the anticonvulsant potency of fenfluramine and norfenfluramine in mice.

Epilepsia·2025
Same author

Folate transfer in placental choriocarcinoma cells treated with valproic acid: Insights gained through comparisons with the amide derivative sec-butylpropylacetamide and its individual stereoisomers.

Epilepsia·2025
Same author

From barbiturates to ganaxolone: The importance of chirality in drug development and in understanding the actions of old and new antiseizure medications.

Pharmacology & therapeutics·2025

Researchers are developing improved valproic acid (VPA) derivatives as next-generation antiepileptic drugs (AEDs). These new compounds aim for enhanced efficacy and safety, addressing limitations of current VPA treatments.

Area of Science:

  • Medicinal Chemistry
  • Neuropharmacology
  • Drug Discovery

Background:

  • Valproic acid (VPA) is a widely used antiepileptic drug (AED) also indicated for migraine prophylaxis and bipolar disorder.
  • Current AEDs, including VPA, manage epilepsy symptoms but not the underlying cause, necessitating long-term treatment.
  • VPA's therapeutic use is constrained by its relatively low potency and significant side effects like teratogenicity and hepatotoxicity.

Purpose of the Study:

  • To conduct structure-activity relationship (SAR) studies on novel CNS-active compounds derived from VPA.
  • To identify potential second-generation VPA drugs with improved efficacy and safety profiles.
  • To guide the development of new antiepileptic therapies that overcome VPA's limitations.

Main Methods:

Related Experiment Videos

  • Synthesis of VPA derivatives.
  • Evaluation of CNS activity through structure-activity relationship analysis.
  • Assessment of antiepileptic potential and safety parameters (teratogenicity, hepatotoxicity).
  • Pharmacokinetic profiling and drug interaction potential assessment.

    • Main Results:

    • Identification of VPA derivatives exhibiting promising CNS activity.
    • Characterization of SAR trends guiding further optimization.
    • Preliminary data suggesting potential for reduced toxicity compared to VPA.
    • Evaluation of pharmacokinetic properties for potential clinical utility.

    Conclusions:

    • The developed VPA derivatives show potential as next-generation antiepileptic drugs.
    • SAR studies provide a foundation for designing safer and more potent AEDs.
    • Further research is warranted to fully elucidate the therapeutic potential and safety of these novel compounds.